-
Something wrong with this record ?
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
A. Bex, YA. Ghanem, L. Albiges, S. Bonn, R. Campi, U. Capitanio, S. Dabestani, M. Hora, T. Klatte, T. Kuusk, L. Lund, L. Marconi, C. Palumbo, G. Pignot, T. Powles, N. Schouten, M. Tran, A. Volpe, J. Bedke
Language English Country Switzerland
Document type Journal Article, Practice Guideline
- MeSH
- Carcinoma, Renal Cell * therapy diagnosis MeSH
- Humans MeSH
- Kidney Neoplasms * therapy diagnosis MeSH
- Societies, Medical MeSH
- Urology standards MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Geographicals
- Europe MeSH
BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU) renal cell carcinoma (RCC) guideline panel has updated their evidence-based guidelines and recommendations for the management of RCC. Here we present a summary of the 2025 RCC guidelines updated with standardised methodology to provide reproducible evidence for the management of RCC. METHODS: For the 2025 update, a literature search was performed covering the period from May 1, 2023 to May 1, 2024 using the Medline, EMBASE, and Cochrane Libraries. The data search focused on meta-analyses, systematic reviews, randomised controlled trials (RCTs), and retrospective or controlled comparator-arm studies. Evidence was synthesised as outlined for all EAU guidelines. KEY FINDINGS AND LIMITATIONS: Clinical practise recommendations were updated in all chapters of the RCC guidelines on the basis of a structured literature search. The studies included were predominantly retrospective with matched or unmatched cohorts based on single- or multi-institutional data. Several prospective studies and RCTs provided data that resulted in recommendations based on higher levels of evidence. Specifically, updates include new recommendations on stereotactic body radiotherapy for localised RCC, adjuvant therapy, systemic therapy for clear-cell RCC in later lines, other subtypes, and a new chapter on hereditary RCC. CONCLUSIONS AND CLINICAL IMPLICATIONS: The 2025 RCC guidelines have been updated by a multidisciplinary panel of experts using methodological standards to provide a contemporary evidence base for the management of RCC.
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Surgical Oncology Institut Paoli Calmettes Marseille France
Department of Translational Medicine Division of Urological Cancers Lund University Malmö Sweden
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Helios Hospital Bad Saarow Germany
Department of Urology San Raffaele Scientific Institute Milan Italy
Department of Urology University of Eastern Piedmont Maggiore della Carità Hospital Novara Italy
Division of Surgery and Interventional Science University College London London UK
Division of Surgery and Interventional Sciences University College London London UK
European Association of Urology Arnhem The Netherlands
Homerton University Hospital London to now Addenbrooke's Hospital Cambridge UK
Royal Free London NHS Foundation Trust London UK
Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
Specialist Centre for Kidney Cancer Royal Free Hospital London UK
Unit of Urology and Renal Transplantation Careggi Hospital Florence Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015525
- 003
- CZ-PrNML
- 005
- 20250731091040.0
- 007
- ta
- 008
- 250708s2025 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2025.02.020 $2 doi
- 035 __
- $a (PubMed)40118739
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Bex, Axel $u Royal Free London NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.bex@ucl.ac.uk
- 245 10
- $a European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update / $c A. Bex, YA. Ghanem, L. Albiges, S. Bonn, R. Campi, U. Capitanio, S. Dabestani, M. Hora, T. Klatte, T. Kuusk, L. Lund, L. Marconi, C. Palumbo, G. Pignot, T. Powles, N. Schouten, M. Tran, A. Volpe, J. Bedke
- 520 9_
- $a BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU) renal cell carcinoma (RCC) guideline panel has updated their evidence-based guidelines and recommendations for the management of RCC. Here we present a summary of the 2025 RCC guidelines updated with standardised methodology to provide reproducible evidence for the management of RCC. METHODS: For the 2025 update, a literature search was performed covering the period from May 1, 2023 to May 1, 2024 using the Medline, EMBASE, and Cochrane Libraries. The data search focused on meta-analyses, systematic reviews, randomised controlled trials (RCTs), and retrospective or controlled comparator-arm studies. Evidence was synthesised as outlined for all EAU guidelines. KEY FINDINGS AND LIMITATIONS: Clinical practise recommendations were updated in all chapters of the RCC guidelines on the basis of a structured literature search. The studies included were predominantly retrospective with matched or unmatched cohorts based on single- or multi-institutional data. Several prospective studies and RCTs provided data that resulted in recommendations based on higher levels of evidence. Specifically, updates include new recommendations on stereotactic body radiotherapy for localised RCC, adjuvant therapy, systemic therapy for clear-cell RCC in later lines, other subtypes, and a new chapter on hereditary RCC. CONCLUSIONS AND CLINICAL IMPLICATIONS: The 2025 RCC guidelines have been updated by a multidisciplinary panel of experts using methodological standards to provide a contemporary evidence base for the management of RCC.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x terapie $x diagnóza $7 D002292
- 650 12
- $a nádory ledvin $x terapie $x diagnóza $7 D007680
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 _2
- $a urologie $x normy $7 D014572
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Ghanem, Yasmin Abu $u Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
- 700 1_
- $a Albiges, Laurence $u Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- 700 1_
- $a Bonn, Stephanie $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Campi, Riccardo $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Urology and Renal Transplantation, Careggi Hospital, Florence, Italy
- 700 1_
- $a Capitanio, Umberto $u Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy
- 700 1_
- $a Dabestani, Saeed $u Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden
- 700 1_
- $a Hora, Milan $u Department of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
- 700 1_
- $a Klatte, Tobias $u Department of Urology, Helios Hospital, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany
- 700 1_
- $a Kuusk, Teele $u Homerton University Hospital London to now Addenbrooke's Hospital, Cambridge, UK
- 700 1_
- $a Lund, Lars $u Department of Urology, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark
- 700 1_
- $a Marconi, Lorenzo $u Department of Urology, Coimbra University Hospital, Coimbra, Portugal
- 700 1_
- $a Palumbo, Carlotta $u Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore Della Carità Hospital, Novara, Italy
- 700 1_
- $a Pignot, Geraldine $u Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France
- 700 1_
- $a Powles, Thomas $u Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK
- 700 1_
- $a Schouten, Natasha $u European Association of Urology, Arnhem, The Netherlands
- 700 1_
- $a Tran, Maxine $u Division of Surgery and Interventional Sciences, University College London, London, UK; Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK
- 700 1_
- $a Volpe, Alessandro $u Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy
- 700 1_
- $a Bedke, Jens $u Department of Urology and Transplantation Surgery and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 87, č. 6 (2025), s. 683-696
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40118739 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091035 $b ABA008
- 999 __
- $a ok $b bmc $g 2366396 $s 1252650
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 87 $c 6 $d 683-696 $e 20250320 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20250708
